Inhibitory effect of honokiol on furin-like activity and SARS-CoV-2 infection

Takashi Tanikawa a,*, 1, Tsuyoshi Hayashi b, 1, Ryuichiro Suzuki c, Masashi Kitamura d, **, Yutaka Inoue e

a Laboratory of Nutri-Pharmacotherapeutics Management, School of Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, Saitama, Japan
b Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
c Laboratory of Natural Products & Phytochemistry, Department of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, Saitama, Japan
d Laboratory of Pharmacognosy, School of Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, Saitama, Japan

Abstract

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a pandemic and has caused damage to the lives of the people and economy of countries. However, the therapeutic reagents against SARS-CoV-2 remain unclear. The spike (S) protein of SARS-CoV-2 contains a cleavage motif at the S1/S2 boundary, known to be cleaved by furin. As cleavage is essential for S protein activation and viral entry, furin was selected as the target compound. In this study, we examined the inhibitory effects of two lignans (honokiol and magnolol) on furin-like enzymatic activity using a fluorogenic substrate with whole-cell lysates. Of two compounds tested, honokiol partially inhibited furin-like enzymatic activity. We further examined the anti-SARS-CoV-2 activity of honokiol using VeroE6 cell line, which is stably expressing a transmembrane protease serine 2 (TMPRSS2). It was shown that honokiol exhibited remarkable inhibition of SARS-CoV-2 infection. Therefore, honokiol and crude drugs which contain honokiol such as Magnolia species have a potential therapeutic reagents for SARS-CoV-2.

© 2021 Center for Food and Biomolecules, National Taiwan University. Production and hosting by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading worldwide, causing over 196 million cases of coronavirus disease 2019 (COVID-19) along with more than 4,200,412 deaths (https://covid19.who.int/accessed July 28, 2021). The entry of SARS-CoV-2 into host cells is mediated by the transmembrane spike glycoprotein (S protein), which forms homo-trimers extending from the virus envelope.2–4 The S protein is processed and activated by cellular proteases, including a transmembrane protease serine 2 (TMPRSS2), cathepsin, and furin; it comprises two functional subunits, S1 and S2. The S1 subunit is involved in binding to the host cell receptor, and the S2 subunit participates in the fusion of the virus envelope and host cell membrane.5,6 S protein cleavage occurs at the boundary between the S1 and S2 subunits. The S1 subunit of SARS-CoV-2 initiates virus-receptor binding by interacting with the human host cell receptor angiotensin-converting enzyme 2, and the S2 subunit participates in viral fusion with the target cell.1 The SARS-CoV-2 S protein possesses a multibasic cleavage site for furin at the S1/S2 boundary, which contributes to the activation of the fusion machinery of the virus.8–10

Furin, belonging to the proprotein convertase family, is a...
calcium-dependent serine endoprotease that cleaves the processing
sites of a precursor protein.10 It is ubiquitously expressed and
circulates among the trans-Golgi network, plasma membrane, and
eyelessome and is associated with endocytic and exocytic
pathways.11 Furin regulates several physiological pathways,
including those of hormones, growth factors, adhesion molecules,
and cell surface receptors.12 It also cleaves pathogen-derived pro-
teins, such as viral envelope proteins and bacterial toxins.13 The
sequence at the S1/S2 boundary of the S protein contains a furin
cleavage site (RRAR S). The multibasic cleavage site in the S protein
is essential for SARS-CoV-2 entry into lung cells, and furin in-
hibitors block S protein processing and SARS-CoV-2 infection.5
Therefore, furin inhibitors are potential antiviral agents for SARS-
CoV-2 infection and pathogenesis.14

Honokiol and magnolol, which are lignans isolated from
Magnolia species, are active components of the Magnoliae Cortex.
The bark of Magnolia species, such as M. officinalis and M. obtusata
is widely used in traditional Chinese and Japanese herbal medicine
for the treatment of gastrointestinal disorders, anxiety, and al-
lergies.15 Other reported actions include neuroprotective, anti-
microbial, anti-inflammatory, and anticancer properties.16–18
Honokiol and magnolol have also been reported to have not only
anti-inflammatory, antiallogenic, antidepressant, antioxidant, and
anticancer effects, but also antivirus effects (supplemental table).16,21–23
In this study, we explored honokiol as a potential
inhibitor of furin, an enzyme involved in the viral entry to the cell.
We further tested if honokiol suppressed viral infection in the
whole cell assay of SARS-CoV-2 infection.

2. Materials and methods

2.1. Materials

Honokiol (>95.0%) and magnolol (>98.0%) were purchased from
Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). Cinnamic acid
(>99.5%) was purchased from FUJIFILM Wako Pure Chemical Cor-
poration (Osaka, Japan). Decanoyl-Arg-Val-Lys-Arg-CMK (Dec-
anoyl-RVKR-CMK) was obtained from Cayman Chemical Company
(MI, USA).

2.2. Furin-like assay

Inhibition assays of furin-like activities were performed according
to a previous report with minor modifications.24 Briefly, AS49 cells (JCRB0076) were cultured and maintained in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 1-glutamine, 100 U/mL penicillin, and 100 μg/
ml streptomycin. The cultured cells were scraped and washed with
ice-cold Dulbecco’s phosphate-buffered saline (D-PBS). Cell
counting was performed and lysis buffer (200 mM HEPES-KOH,
100 μM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES-
KOH), pH 7.4, 0.1% Triton X-100, 10 mM calcium chloride) was added to
the cell precipitate. The cell lysates were centrifuged at 13,000 × g
for 10 min at 4 °C, and the supernatant was transferred to new
tubes and stored at −80 °C until use. The furin-like enzymatic assay
was performed as follows: 10 μl honokiol, magnolol, or cinnamic
acid and 50 μl cell lysates were added to a 96-well plate containing
30 μl MilliQ water and incubated at 37 °C for 30 min. The reaction
mixture and 10 μl 1 mM furin fluorogenic substrate, Pyr-Arg-Thr-
Lys-Arg-MCA (PEPTIDE INSTITUTE, Inc., Osaka, Japan) or Pyr-Arg-
Arg-Ala-Arg-MCA (Greiner Bio-One, Austria) were mixed and
incubated at 37 °C for 30 min. Fluorescence intensity was measured
with excitation at 380 nm and emission at 460 nm.

2.3. Honokiol treatment and SARS-CoV-2 infection

Vero E6/TMPRSS2 cells (JCRB1819, Vero E6 cells overexpressing
TMPRSS2) were purchased from JCRB Cell Bank (Osaka, Japan) and
cultured in DMEM supplemented with 10% FBS, 100 U/mL peni-
cillin, 100 μg/mL streptomycin, and 1 mg/mL G418 (Nacalai Tesque,
Kyoto, Japan).25 Cell viability in Vero E6/TMPRSS2 cells treated with
honokiol was determined using CellTiter-Glo® Luminescent Cell
Viability Assay (Promega, Madison, WI, USA). The SARS-CoV-2
infection studies were done in a biosafety level 3 facility at Na-
tional Institute of Infectious Diseases, Japan. A previously isolated
2019-nCoV/Japan/TY/WK-521/2020 strain (WK-521) of SARS-CoV-
2 was propagated in Vero E6/TMPRSS2 cells.26 The viral titer of
SARS-CoV-2 was determined through a 50% tissue culture infectious
dose (TCID50) assay in Vero E6/TMPRSS2 cells.27 Confluent Vero E6/
TMPRSS2 cells cultured in a 96-well plate (CellCarrier-96 Ultra,
PerkinElmer, Waltham, MA, USA) were pre-treated with honokiol
dissolved in DMSO at the indicated concentrations without agita-
tion for 1 h at 37 °C. The cells were then infected with SARS-CoV-2
at a multiplicity of infection (MOI) of 0.009 in the presence of
honokiol for 24 h at 37 °C. The infected cells were then fixed with
4% paraformaldehyde in D-PBS for 30 min and permeabilized with
0.2% Triton X-100 in D-PBS for 15 min. The cells were stained for
SARS-CoV-2 S protein using rabbit anti-SARS-CoV-2, Spike RBD
clonal antibody (1:3,000, clone HL1003, GTX635792; Gene-
Tex, Irvine, CA, USA), followed by goat anti-rabbit IgG Alexa Fluor
488 (1:1,000, Life Technologies, Carlsbad, CA, USA). Cell nuclei
were stained with 1 μg/ml 4′,6-diamidino-2-phenylindole (DAPI)
solution (Dojindo Laboratories, Kumamoto, Japan). The cells were then
imaged using the Operetta CLS High-Content Analysis System
(PerkinElmer), and infectivity (percentage of SARS-CoV-2 positive
cells) in each well was calculated by counting SARS-CoV-2 S-and
DAPI-positive cells using Harmony software (PerkinElmer). Dose
response curve was created by nonlinear regression model, the
half-maximal inhibitory concentration (IC50) and the half-maximal
cytotoxic concentration (CC50) were calculated using GraphPad
Prism 9 software.

3. Results and discussion

3.1. Furin-like assay

Lignans are polyphenolic substances that feature C18 cores,
resulting from the dimerization of phenylpropanoids. We tested
two lignans (honokiol and magnolol) and one phenylpropanoid
(cinnamic acid) for furin-like enzymatic activities. Decanoyl-RVKR-
CMK, a furin inhibitor, was used as a positive control. The furin-like
assay was performed using pyr-RTKR-MCA or pyr-RARR-MCA as
cleavage substrates. With pyr-RTKR-MCA as substrate, honokiol
was determined using CellTiter-Glo® MCA and the half-maximal
inhibitory concentration (IC50) and the half-maximal
cytotoxic concentration (CC50) were calculated using GraphPad

Table 1

| Compound   | conc. | RTRK-MCA | RARR-MCA |
|------------|-------|----------|----------|
| Honokiol   | 100 μM| 71.0 ± 3.0% | 67.3 ± 2.3% |
| Magnolol   | 100 μM| 89.9 ± 0.8% | 85.5 ± 2.1% |
| Cinnamic acid | 100 μM| 83.8 ± 2.5% | 84.0 ± 1.4% |
| Decanoyl-RVKR-CMK | 25 μM| 0.1 ± 0.0% | 0.2 ± 0.0% |
| Control (no sample) |          | 100%      | 100%      |

[mean ± standard deviation (SD), n = 3]
that honokiol has the potential to inhibit multibasic motif cleavage by endogenous proteases.

3.2 SARS-CoV-2 infection

We then evaluated the effect of honokiol on viral infection using Vero E6/TMPRSS2 cells. Treatment of honokiol alone showed no or minor cytotoxicity, except for a highest concentration (100 μM) (Fig. 1A and B). For an infection study, we pretreated Vero E6/TMPRSS2 cells with a dilution series of honokiol (100, 50, 25, 12.5, 6.25, and 3.125 μM) and then infected with SARS-CoV-2 in the presence of honokiol. Cell viability and infectivity were assessed 24 h post-infection (Fig. 1C and D). SARS-CoV-2 infection was suppressed by honokiol in a dose-dependent manner; it completely inhibited viral infection at concentrations of 25 μM (99.83%) and 50 μM (99.96%) with no or minor cytotoxicity (2.49% for 25 μM and 34.5% for 50 μM) (Fig. 1C and D). The IC_{50} values determined by the infection assay were 13.0 μM for honokiol. The concentration (25 μM) of honokiol used to suppress viral infection in Vero E6/TMPRSS2 cells was lower than that (100 μM) used for the inhibitory assay of furin-like activity. This difference in concentrations might be related to a multitarget effect of honokiol in the whole organism assay, as has been reported for other viral infections.23 It has been reported that honokiol blocks phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) signaling in various cell lines and induces autophagy in neuroblastoma cells by activating the PI3K/Akt/mammalian target of rapamycin (mTOR) and endoplasmic reticular stress/extracellular signal-regulated kinase (ERK)1/2 signaling pathways.26 Since honokiol has been used as an Akt inhibitor, the suppressive effect of viral infection might be attributed to properties other than the inhibition of furin-like activities.

Inhibitory effects of virus infection by blocking Akt pathway have been indicated in the previous study on Middle East respiratory syndrome coronavirus (MERS-CoV), which was first identified in 2012 and belongs to the same family and genus as Sars-CoV-2. MERS-CoV infection has been reported to upregulate PI3K/Akt/mTOR, and blocking this pathway significantly inhibited MERS-CoV replication in vitro.27 Reovirus virions activate the PI3K/Akt pathway via clathrin-mediated endocytosis, and it has been shown that SARS-CoV-2 endocytosis occurs through a clathrin-mediated pathway.28,29 A recent study showed that the inhibition of clathrin-dependent endocytosis reduced SARS-CoV-2 infectivity.29 SARS-CoV-2 endocytosis and replication may be associated with the PI3K/Akt/mTOR pathway. Therefore, blocking the PI3K/Akt/mTOR signaling pathway may be important for developing potential therapeutic applications against COVID-19.

Further research is necessary to elucidate the molecular mechanism for the inhibitory effect of honokiol on SARS-CoV-2 infection.

![Fig. 1. Honokiol inhibits SARS-CoV-2 infection in Vero E6/TMPRSS2 cells. (A) The structure of Honokiol. (B) Vero E6/TMPRSS2 cells were treated with honokiol at the indicated concentrations for 24 h. Cell viability was determined using CellTiter-Glo® Luminescent Cell Viability Assay. Results were normalized to those of dimethylsulfoxide (DMSO)-treated cells. (C and D) Vero E6/TMPRSS2 cells were infected with SARS-CoV-2 for 24 h in the presence of the indicated concentration of honokiol, after which the cells were stained with anti-SARS-CoV-2 Spike RBD monoclonal antibody for viral infection and DAPI and analyzed to determine cell number and percent of infection. (C) Representative fluorescence images show SARS-CoV-2 S protein (green) and cell nucleus (blue). Scale bar, 1 mm. (D) The percentages of infected cells and cell numbers were normalized to those of DMSO-treated cells infected with SARS-CoV-2. Values represent the mean ± SD of two independent experiments (n = 6).](image-url)
In this study, we performed in vitro assays to evaluate the inhibitory effect of honokiol on furin-like activity. Evaluating the cleavage of S protein is required as well. It is important to understand whether inhibiting Akt pathway causes the inhibition of SARS-CoV-2 infection, and whether inhibiting both furin and Akt pathways have the synergistic effect on inhibition of SARS-CoV-2 infection. As honokiol is contained in the crude drugs from Magnolia plants used in traditional Chinese medicine and Kampo medicine, the inhibitory effect of conventional formulations that contain these crude drugs on SARS-CoV-2 infection should be test in further study.

In summary, we showed that honokiol partially inhibited furin-like activity in vitro tests, which can potentially inhibit the analog site in the S protein of SARS-CoV-2. We also showed that SARS-CoV-2 infection was suppressed in the presence of honokiol at concentrations that are pharmacologically relevant. Since honokiol is known as an inhibitor of PI3K/Akt signaling in various cell lines, honokiol could inhibit SARS-CoV-2 infection not only by inhibiting furin-like activity but also by blocking PI3K/Akt signaling.

Concent for publication
provided by all authors

Highlights of the findings and novelties
Honokiol inhibits SARS-CoV-2 infection.

Declaration of competing interest
The authors declare no conflict of interest

Acknowledgements
This work was partially supported by JSPS KAKENHI (Grant Number JP20H00259 to T.H. and JP21K15283 to M.K.)

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.jtcmne.2021.09.005.

References
1. Kumar A, Singh R, Kaur J, et al. Wuhan to world: the COVID-19 pandemic. Front Cell Infect Microbiol. 2021;11:596201.
2. Alsobaste S. Understanding the molecular biology of SARS-CoV-2 and the COVID-19 pandemic: a review. Infect Drug Resist. 2021;14:2259–2268.
3. Kalathiya U, Padariya M, Mayordomo M, et al. Highly conserved homotrimer cavity formed by the SARS-CoV-2 spike glycoprotein: a novel binding site. J Clin Med. 2020;9(5):1473.
4. Römer RA, Römer NS, Wallis AK. Flexibility and mobility of SARS-CoV-2-related protein structures. Sci Rep. 2021;11(1):4257.
5. Bestel D, Heindl MB, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance. 2020;3(9), e202000786.
6. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292, e6.
7. Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;78(4):779–784, e5.
8. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117(21):11727–11734.
9. Molloy SS, Bresnahan PA, Leppa SH, Klimpel KR, Thomas G. Human furin is a calcium-dependent serine endopeptidase that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax protective antigen. J Biol Chem. 1992;267(23):16396–16402.
10. Hatsuzawa K, Nagahama M, Takahashi S, Takada K, Murakami K, Nakayama K. Purification and characterization of furin, a Kex2-like processing endopeptidase, produced in Chinese hamster ovary cells. J Biol Chem. 1992;267(23):16094–16099.
11. Voorhees P, Deignan E, van Donselaar E, et al. An acidic sequence within the cytoplasmic domain of furin functions as a determinant of trans-Golgi network localization and internalization from the cell surface. EMBO J. 1995;14(20):4961–4975.
12. Nakayama K. Furin: a mammalian subtilisin/Kex2p-like endopeptidase involved in processing of a wide variety of precursor proteins. Biochem J. 1997;327(3 Pt 3):625–635, Pt 3.
13. Braun E, Sauter D. Furin-mediated protein processing in infectious diseases and cancer. Clin Transl Immunology. 2019;8(8), e1072.
14. Cheng YW, Chao TL, Li CL, et al. Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep. 2020;33(2):108254.
15. Wu C, Zheng M, Yang Y, et al. Furin: a potential therapeutic target for COVID-19. iScience. 2020;23(10):101642.
16. Luo H, Wu H, Yu X, et al. A review of the phytochemistry and pharmacological activities of Magnolia officinalis cortex. J Ethnopharmacol. 2019;236:412–442.
17. Yang EJ, Lee JY, Park SH, Lee T, Song KS. Neuroprotective effects of neolignans isolated from Magnoliae Cortex against glutamate-induced apoptotic stimuli in HT22 cells. Food Chem Toxicol. 2013;56:304–312.
18. Hu X, Qiao J, Zhang X, Ge C. Antimicrobial effect of Magnolia officinalis extract against Staphylococcus aureus. J Sci Food Agric. 2019;91(6):1050–1056.
19. Walker JM, Maitra A, Walker J, Ehrnhoefer-Ressler MM, Inui T, Somoza V. Identification of Magnolia officinalis L bark extract as the most potent anti-inflamatory of four plant extracts. Am J Chin Med. 2013;41(3):531–544.
20. Ha KT, Kim JR, Lee YC, Kim CH. Inhibitory effect of Daesungki-Tang on the invasiveness potential of hepatocellular carcinoma through inhibition of matrix metalloproteinase-2 and -9 activities. Toxicol Appl Pharmacol. 2004;200(1):1–6.
21. Chen X, Hu Y, Shan L, Yu X, Hao K, Wang GX. Magnolol and honokiol from Magnolia officinalis enhanced antiviral immune responses against grass carp reovirus in Ctenopharyngodon idella kidney cells. Fish Shellfish Immunol. 2017;63:245–254.
22. Fang CY, Chen SJ, Wu HN, et al. Honokiol, a lignan biphenol derived from the Magnolia tree, inhibits dengue virus type 2 infection. Viruses. 2015;7(9):4910–4919.
23. Liu S, Li L, Tan L, Liang X. Inhibition of herpes simplex virus-1 replication by natural compound honokiol. Virol Sin. 2019;34(3):315–323.
24. Kiba Y, Oyaama R, Misawa S, Tanikawa T, Kitamura M, Suzuki R. Screening for inhibitory effects of crude drugs on furin-like enzymatic activities. J Nat Med. 2021;1–6.
25. Matsuyma S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A. 2020;117(13):7001–7003.
26. Yeh PS, Wang W, Chang YA, Lin CJ, Wang JY, Chen RM. Honokiol induces autophagy of neuroblastoma cells through activating the PI3K/Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration. Canc Lett. 2016;370(1):66–77.
27. Kindrachuk J, Ork B, Hart BJ, et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother. 2015;59(2):1088–1099.
28. Tian J, Zhang X, Wu H, et al. Blocking the PI3K/AKT pathway enhances mamalian reovirus replication by repressing IFN-stimulated genes. Front Microbiol. 2015;6:886.
29. Bayati A, Kumar R, Francis V, McPherson PS. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. J Biol Chem. 2021;296:100308.